Tag Archives: BioMerieux

← Older posts

Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: LLY) said that […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

Bought By Utah Rival Tute, Former Genomics High Flyer Knome Bows Out

After eight years, more than $20 million raised, and a handful of different business plans, genomics firm Knome has been acquired by tiny Tute Genomics of Provo, UT, for what appears to be a substantial loss. The parties are not disclosing the purchase price, but it’s likely to be a fraction of what Knome investors […]

Posted in Boston, Boston blog main, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bought By Utah Rival Tute, Former Genomics High Flyer Knome Bows Out

T2 Biosystems Sputters Through IPO Queue, Raises $57M

If the question was how a diagnostics company would fare in a sputtering IPO market, the answer for T2 Biosystems was: not too well. The Lexington, MA-based company priced well below its projected range, raising about $57.2 million before paying its underwriters. T2 aimed to raise as much as $68 million by selling 4 million […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

9 Takeaways from Boston’s Life Science Disruptors

Building a biotech is (really) hard. But if you’re doing to do it, be yourself. Don’t take yourself too seriously. Wear sneakers if you feel like it. Near-death experiences happen to everyone along the way—embrace them and learn. And if your initial hunch is that the company’s founding idea is insane, it’s probably worth pursuing. […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on 9 Takeaways from Boston’s Life Science Disruptors

NeuroPhage Pharmaceuticals Secures $6,400,000 New Funding Round

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b5118b94-342d-4512-bb0a-51b945378589&Preview=1 Date 5/6/2013 Company Name NeuroPhage Pharmaceuticals Mailing Address 222 3rd St. Cambridge, MA 02142 Company Description NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique […]

Posted in Boston, Boston VentureDeal VC | Tagged , , , , | Comments Off on NeuroPhage Pharmaceuticals Secures $6,400,000 New Funding Round

Moderna, $40M in Tow, Hopes to Reinvent Biotech with “Make Your Own Drug”

Noubar Afeyan, Bob Langer, Tim Springer, and a host of other Boston biotech luminaries have been sitting on a big secret. Today we’re going to out them. Moderna Therapeutics, a stealthy startup in Cambridge, MA, is the subject of their considerable brainpower and experiments. The company is finally emerging from stealth, having raised $40 million […]

Posted in Boston, Boston blog main, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | 16 Comments

Celgene Pumps Up Acceleron, On-Q-ity CEO Goes to Roche Unit, MSMB Eyes Amag, & More Boston-Area Life Sciences News

We caught some personnel updates and other news from public and private New England companies developing drugs, medical devices, and diagnostics technology. —Woburn, MA-based Pathogenetix, the diagnostics and biodefense company formerly known as U.S. Genomics, raised $4 million of a targeted $9.5 million equity financing. —Beacon Endoscopic, a Newton, MA-based startup that’s developed a fine […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Celgene Pumps Up Acceleron, On-Q-ity CEO Goes to Roche Unit, MSMB Eyes Amag, & More Boston-Area Life Sciences News

Stéphane Bancel, Former bioMérieux CEO, Talks Future of Startups, Diagnostics, Pharma

Amid all the comings and goings and CEOs changing jobs in the past week—see Rick Reidy of Progress Software (NASDAQ: PRGS), Mara Aspinall of On-Q-ity, and others—one person flew under the radar in Boston. He is Stéphane Bancel, and until last month he was the CEO of bioMérieux, the microbiology and diagnostics firm based in […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 44 Comments

NeuroPhage Pharmaceuticals Garners $12,400,000 Series B Financing

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ad05020f-0c6a-45f6-9111-8c4c2cb69ca4&Preview=1 Date 3/1/2011 Company Name NeuroPhage Pharmaceuticals Mailing Address 222 3rd St. Cambridge, MA 02142 Company Description NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique […]

Posted in Boston, Boston VentureDeal VC | Tagged , , , | Comments Off on NeuroPhage Pharmaceuticals Garners $12,400,000 Series B Financing

Warner Bros. Acquires Turbine, Athenahealth Taps IBM, Alkermes Reveals Diabetes Drug Royalty, & More Boston-Area Deals News

News of financings, partnerships, royalties, and acquisitions among New England’s video game, transportation, biotech, and energy companies have kept us buzzing in the last week. —Westwood, MA-based online games maker Turbine was purchased by the Home Entertainment Group of Warner Bros. Interactive Entertainment, a unit of Time Warner (NYSE: TWX). Turbine produces the massively multiplayer […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Warner Bros. Acquires Turbine, Athenahealth Taps IBM, Alkermes Reveals Diabetes Drug Royalty, & More Boston-Area Deals News← Older posts